Rise and shine, everyone, another busy day is on the way. There is already considerable movement here at the Pharmalot campus, where the short person successfully departed for the local schoolhouse, despite the usual last-minute hurdles and challenges. Such accomplishments call for a cup of stimulation, which is heating in the coffee kettle as we assemble this menu of tidbits for you. However, this is also the signal to get cracking. So on that note, we will wish you a splendid day and offer a reminder that we are happy to accept confidential documents and recordings …

Illinois lawmakers are considering a bill that would guard non-medical switching, which refers to an insurer changing coverage in the middle of a plan year, even though most plan participants are locked in, the Chicago Tribune tells us. The proposed bill would prohibit commercial health insurers from modifying coverage of a drug during the plan year if it has previously approved the drug for a medical condition. It would not prevent plans from requiring pharmacists to give generic substitutions or from adding new drugs for coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I think it’s wrong to make a person subscribe to your newsletter without even letting a person read a whole article. Is that to much to ask.
    I said to myself let me read this article and if I don’t find anything missing or opinionated in it, I’ll subscribe.
    I won’t now.
    Rh

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy